- Conditions
- Depression, Anxiety, Suicidal Ideation
- Interventions
- Adaptive messaging intervention, Non-personalized messaging intervention, Coaching, Psychoeducational links
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1945–1968
of 17,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Persistent Postsurgical Pain
- Interventions
- Not listed
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Disease
- Interventions
- ICA-17043
- Drug
- Lead sponsor
- Icagen
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 347
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI, BI 201335 NA 240 mg QD, BI 201335 NA 240 mg BID, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more
- Conditions
- Coronary Disease
- Interventions
- regadenoson
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
- Interventions
- FK-PC101, Standard of Care (SOC)
- Biological
- Lead sponsor
- Cellvax Therapeutics Inc
- Industry
- Eligibility
- Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Screening Phase, Discontinuation Phase
- Other · Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Postpartum Depression
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 1,341,172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Davis, California • San Francisco, California • Chicago, Illinois + 4 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- TV-1106, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 25
- States / cities
- Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
- Conditions
- Hypercholesterolemia
- Interventions
- PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more
- Conditions
- Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
- Interventions
- Aminophylline, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Drug · Other
- Lead sponsor
- ITM Solucin GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Mylotarg
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 59
- States / cities
- Tucson, Arizona • Berkely, California • Burbank, California + 49 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 26 more
- Conditions
- Trichotillomania (Hair-Pulling Disorder), Dermatillomania
- Interventions
- Placebo, Aripiprazole
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 499
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
- Conditions
- Parents
- Interventions
- HPV Vaccine Education, Text Messaging Reminder
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 84 Years
- Enrollment
- 672 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Las Vegas, Nevada • New York, New York + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
- Conditions
- Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • Bethesda, Maryland + 2 more
- Conditions
- Hematologic Malignancies
- Interventions
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
- Device · Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo, Standard of Care
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 16
- States / cities
- Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
- Conditions
- Cystic Fibrosis
- Interventions
- FTI, AZLI, Placebo, AZLI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 36
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more